Pattern of Statin Exposures Reported to Texas Poison Centers, 1998–2004

REFERENCES

• Blankenhorn , K. and Lipson , D. 2002 . Business watch: 2001 In review: Despite economic challenges, pharmaceutical industry still maintains steady growth . Med. Mark. Med. , 37 : 46 – 62 .
   Google Scholar
• Brousseau , M. E. 2003 . Statins, super-statins and cholesterol absorption inhibitors . IDrugs. , 6 : 458 – 463 .
   PubMed Web of Science ®Google Scholar
• Carroll , M. D. , Lacher , D. A. , Sorlie , P. D. , Cleeman , J. I. , Gordon , D. J. , Wolz , M. , Grundy , S. M. and Johnson , C. L. 2005 . Trends in serum lipids and lipoproteins of adults, 1960–2002 . J. Am. Med. Assoc. , 294 : 1773 – 1781 .
   PubMed Web of Science ®Google Scholar
• Cherry , D. K. , Burt , C. W. and Woodwell , D. A. 2003 . National Ambulatory Medical Care Survey: 2001 Summary . Adv. Data , 337 : 1 – 44 .
   Google Scholar
• Hsu , I. , Spinler , S. A. and Johnson , N. E. 1995 . Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia . Ann. Pharmacother. , 29 : 743 – 759 .
   PubMed Web of Science ®Google Scholar
• Jones , P. H. , Davidson , M. H. , Stein , E. A. , Bays , H. E. , McKenney , J. M. , Miller , E. , Cain , V. A. , Blasetto , J. W. and STELLAR Study Group . 2003 . Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR∗ Trial) . Am. J. Cardiol. , 92 : 152 – 160 .
   PubMed Web of Science ®Google Scholar
• Lennernas , H. and Fager , G. 1997 . Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences . Clin. Pharmacokinet. , 32 : 403 – 425 .
   PubMed Web of Science ®Google Scholar
• Ma , J. , Sehgal , N. L. , Ayanian , J. Z. and Stafford , R. S. 2005 . National trends in statin use by coronary heart disease risk category . PLoS. Med. , 2 : e123
   Web of Science ®Google Scholar
• Manoguerra , A. S. , Erdman , A. R. , Booze , L. L. , Christianson , G. , Wax , P. M. , Scharman , E. J. , Woolf , A. D. , Chyka , P. A. , Keyes , D. C. , Olson , K. R. , Caravati , E. M. and Troutman , W. G. 2005 . Iron ingestion: An evidence-based consensus guideline for out-of-hospital management . Clin. Toxicol. (Phil.a. , 43 : 553 – 570 .
   PubMed Web of Science ®Google Scholar
• McKenney , J. M. 2005 . Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: Benefits versus risks . Am. J. Cardiol. , 96 : 60E – 66E .
   PubMed Web of Science ®Google Scholar
• McKenney , J. M. , Jones , P. H. , Adamczyk , M. A. , Cain , V. A. , Bryzinski , B. S. , Blasetto , J. W. and STELLAR Study Group . 2003 . Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: Results from the STELLAR trial . Curr. Med. Res. Opin. , 19 : 689 – 698 .
   PubMed Web of Science ®Google Scholar
• Schiff , G. D. , Keehr , L. M. , Sai , T. T. and Bult , J. 2002 . High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic . Pharmacoepidemiol. Drug Safety , 11 : 643 – 645 .
   PubMed Web of Science ®Google Scholar
• SoRelle , R. 2001 . Baycol withdrawn from market . Circulation , 104 : E9015 – E9016 .
   Google Scholar
• Wax , P. M. , Erdman , A. R. , Chyka , P. A. , Keyes , D. C. , Caravati , E. M. , Booze , L. , Christianson , G. , Woolf , A. , Olson , K. R. , Manoguerra , A. S. , Scharman , E. J. and Troutman , W. G. 2005 . Beta-blocker ingestion: An evidence-based consensus guideline for out-of-hospital management . Clin. Toxicol. (Phila.) , 43 : 131 – 146 .
   PubMed Web of Science ®Google Scholar
• Woodwell , D. A. and Cherry , D. K. 2004 . National Ambulatory Medical Care Survey: 2002 Summary . Adv. Data , 346 : 1 – 44 .
   PubMedGoogle Scholar